Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Inflammatory Bowel Diseases

Free Subscription 16.02.2026 1 Aliment Pharmacol Ther 3 Am J Gastroenterol 1 BMC Gastroenterol 1 Clin Exp Immunol 1 Clin Gastroenterol Hepatol 2 Dis Colon Rectum 5 Gastroenterology 1 Gut 9 Inflamm Bowel Dis 2 J Clin Gastroenterol 2 J Crohns Colitis 3 Lancet Gastroenterol Hepatol 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. AHUJA D, Park SK, Yeh KH, Patel SB, et al
   Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases.
   Aliment Pharmacol Ther. 2026;63:686-695.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. KOCHAR B, Faye AS, Araka E, Glasser R, et al
   The bidirectional relationship between cognitive function and active inflammatory bowel disease.
   Am J Gastroenterol. 2026 Feb 13. doi: 10.14309/ajg.0000000000003965.
   PubMed         Abstract available
   
   
3. SHEEHAN JL, Clauw DJ, Singh P, Lee A, et al
   Nociplastic Pain is Associated with Increased Healthcare Utilization and Lower Quality of Life in Patients with Inflammatory Bowel Disease.
   Am J Gastroenterol. 2026 Feb 12. doi: 10.14309/ajg.0000000000003948.
   PubMed         Abstract available
   
   
4. ZURBUCH E, Mahadevan U, Shah S, Zhang X, et al
   Prior Abdominal Surgery is Not Associated with Adverse Pregnancy, Delivery or Neonatal Outcomes in Women with Crohn's Disease: Results from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes (PIANO) Study.
   Am J Gastroenterol. 2026 Feb 11. doi: 10.14309/ajg.0000000000003947.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. LOUSADA JDM, Peluso C, Bianco B, Maselli-Schoueri JH, et al
   Hospitalization rate for ulcerative colitis and Crohn's disease in Brazil and its correlation with socioeconomic inequalities.
   BMC Gastroenterol. 2026 Feb 7. doi: 10.1186/s12876-026-04633.
   PubMed         Abstract available
   
   

   
   Clin Exp Immunol

6. VIEUJEAN S, Jacobs N, Fernandez-Verdejo R, Fraussen J, et al
   Higher humoral response in ileal versus colonic Crohn's disease.
   Clin Exp Immunol. 2026 Feb 11:uxag005. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

7. JENA A, Chatterjee A, Choudhury A, Sharma V, et al
   Effectiveness and safety of JAK inhibitors in acute severe ulcerative colitis: A systematic review and meta-analysis.
   Clin Gastroenterol Hepatol. 2026 Feb 12:S1542-3565(26)00106.
   PubMed         Abstract available
   
   

   
   Dis Colon Rectum

8. MORITA S, Okabayashi K, Kitagawa Y, Okita Y, et al
   Textbook Outcome After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Nationwide Multicenter Study and Its Implications for Long-Term Quality of Life.
   Dis Colon Rectum. 2026 Feb 13. doi: 10.1097/DCR.0000000000004157.
   PubMed         Abstract available
   
   
9. REYES DIAZ ML, Hinojosa Ramirez F, Olmo Santiago R, Ramallo Solis IM, et al
   Treatment of Anal Fistula in Crohn's Disease With Platelet-Rich Plasma: Long-term Results.
   Dis Colon Rectum. 2026 Feb 12. doi: 10.1097/DCR.0000000000004185.
   PubMed         Abstract available
   
   

   
   Gastroenterology

10. BEECHAM AH, McGovern DPB, Brugger SW, Davis MF, et al
    Genomic Insights Into Inflammatory Bowel Disease in United States Hispanic Participants: An Ancestry-Focused Study.
    Gastroenterology. 2026 Feb 9:S0016-5085(25)06484.
    PubMed         Abstract available
    
    
11. HASKEY N, Ye J, Lewis A, Yousuf M, et al
    Time-Restricted Feeding Reduces Body Mass Index, Visceral Adiposity, Systemic Inflammation, and Clinical Disease Activity in Adults With Crohn's Disease: A Randomized Controlled Study.
    Gastroenterology. 2026 Feb 9:S0016-5085(25)06485.
    PubMed        
    
    
12. VESTERGAARD MV, Allin KH, Nohr AK, Torresano Lominchar JV, et al
    Genetic Risk of Inflammatory Bowel Disease Is Associated With Disease Course Severity.
    Gastroenterology. 2026 Feb 10:S0016-5085(25)06019.
    PubMed         Abstract available
    
    
13. REINISCH W, Rittscher J, Iacucci M, Travis S, et al
    Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease.
    Gastroenterology. 2026 Feb 10:S0016-5085(25)06588.
    PubMed         Abstract available
    
    
14. O'CONNOR G, Hazime H, Burgueno JF, Fernandez I, et al
    Quorum sensing molecules are elevated in long-standing ulcerative colitis and are linked to the development of colitis-associated cancer.
    Gastroenterology. 2026 Feb 11:S0016-5085(26)00090.
    PubMed         Abstract available
    
    

    
    Gut

15. POWELL N
    Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted?
    Gut. 2026 Feb 13:gutjnl-2025-336049. doi: 10.1136/gutjnl-2025-336049.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

16. DUBINSKY MC, Chaparro M, Irving PM, Hur P, et al
    Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.
    Inflamm Bowel Dis. 2026 Feb 8:izaf333. doi: 10.1093.
    PubMed         Abstract available
    
    
17. SOLITANO V, Peyrin-Biroulet L, Vermeire S, Dubinsky MC, et al
    Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.
    Inflamm Bowel Dis. 2026 Feb 10:izaf315. doi: 10.1093.
    PubMed         Abstract available
    
    
18. TAKENAKA K, Kawamoto A, Hibiya S, Tamura A, et al
    Stricture dynamics and prognosis during biologic therapy in ileal Crohn's disease: a real-world cohort.
    Inflamm Bowel Dis. 2026 Feb 10:izag012. doi: 10.1093.
    PubMed         Abstract available
    
    
19. RICCIUTO A, Turinsky AL, Griffiths AM, Mack DR, et al
    Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort.
    Inflamm Bowel Dis. 2026 Feb 11:izaf329. doi: 10.1093.
    PubMed         Abstract available
    
    
20. COLWILL M, Patel K, Sebastian S, Din S, et al
    Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology.
    Inflamm Bowel Dis. 2026 Feb 11:izaf334. doi: 10.1093.
    PubMed         Abstract available
    
    
21. LI DK, Chaar A, Arabi T, Quraishi MN, et al
    Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026 Feb 12:izag001. doi: 10.1093.
    PubMed         Abstract available
    
    
22. RUBIN DT, Danese S, Nakase H, Ungaro RC, et al
    Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis.
    Inflamm Bowel Dis. 2026 Feb 12:izaf319. doi: 10.1093.
    PubMed         Abstract available
    
    
23. DELL'ERA A, Antonelli E, Fousekis FS, Katsanos KH, et al
    Persistent Abdominal Pain in Patients with Inactive Inflammatory Bowel Disease: A Clinical Conundrum.
    Inflamm Bowel Dis. 2026 Feb 12:izaf327. doi: 10.1093.
    PubMed         Abstract available
    
    
24. ORTOFT F, Nissen MJ, Kjeldsen J, Steenholdt C, et al
    Acute severe ulcerative colitis without systemic toxicity: A retrospective multicenter cohort study suggesting refining the definition of acute severe ulcerative colitis.
    Inflamm Bowel Dis. 2026 Feb 12:izaf323. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

25. LIU L, Yao Y, Li S
    Comments on "Suicide Attempts, Schizophrenia, and Depression Among Inflammatory Bowel Disease Patients"??????: Data From a Large Database.
    J Clin Gastroenterol. 2026 Feb 9. doi: 10.1097/MCG.0000000000002345.
    PubMed        
    
    
26. NGUYEN B, Quon S, Williams AJ, Leung Y, et al
    Safety of Vedolizumab in Pregnancy: An Updated Systematic Review and Comprehensive Meta-analysis.
    J Clin Gastroenterol. 2026;60:225-231.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

27. CENTANNI L, Fanizzi F, D'amico F, Danese S, et al
    Cutaneous autoimmune blistering disease during mirikizumab therapy in a patient with ulcerative colitis: a new potential trigger?
    J Crohns Colitis. 2026 Feb 13:jjaf235. doi: 10.1093.
    PubMed         Abstract available
    
    
28. SAGAMI S, Matsuoka K, Kobayashi T
    Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis.
    J Crohns Colitis. 2026;20:jjaf224.
    PubMed        
    
    

    
    Lancet Gastroenterol Hepatol

29. D'HAENS GR, Oldenburg L, Hulshoff MS
    Vedolizumab treatment outcomes in early versus late Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:184-185.
    PubMed        
    
    
30. CHEN R, Croitoru K, Lee SH
    Vedolizumab treatment outcomes in early versus late Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:183-184.
    PubMed        
    
    
31. NOOR NM, Hart AL, Lee JC, Parkes M, et al
    Vedolizumab treatment outcomes in early versus late Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:182-183.
    PubMed        
    
    

    
    PLoS One

32. LIVIERATOS A, Kudela M, Zhao Y, Chen AS, et al
    MetaMind: A multi-agent transformer-driven framework for automated network meta-analyses.
    PLoS One. 2026;21:e0342895.
    PubMed         Abstract available
    
    
33. LIU D, Dan W, Yan B, Peng L, et al
    Evidence for genetic correlation between appendix and inflammatory bowel disease: A bidirectional Mendelian randomization study.
    PLoS One. 2026;21:e0342541.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum